9.38
Precedente Chiudi:
$9.27
Aprire:
$9.26
Volume 24 ore:
585.48K
Relative Volume:
0.37
Capitalizzazione di mercato:
$2.95B
Reddito:
$2.68B
Utile/perdita netta:
$-184.45M
Rapporto P/E:
-13.78
EPS:
-0.6805
Flusso di cassa netto:
$229.23M
1 W Prestazione:
+0.54%
1M Prestazione:
+16.38%
6M Prestazione:
+11.27%
1 anno Prestazione:
+10.74%
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Confronta AMRX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
AMRX
Amneal Pharmaceuticals Inc
|
9.38 | 2.91B | 2.68B | -184.45M | 229.23M | -0.6805 |
![]()
ZTS
Zoetis Inc
|
154.88 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.88 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
![]()
HLN
Haleon Plc Adr
|
9.63 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.14 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
![]()
UTHR
United Therapeutics Corp
|
309.22 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-06 | Iniziato | Goldman | Buy |
2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-07-27 | Iniziato | Goldman | Sell |
2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2019-06-11 | Iniziato | Barclays | Equal Weight |
2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
2019-03-20 | Iniziato | SunTrust | Buy |
2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2018-10-16 | Downgrade | SunTrust | Buy → Hold |
2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2018-07-23 | Iniziato | Morgan Stanley | Overweight |
2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Amneal Pharmaceuticals Inc. Breaks Losing Streak — Is the Trend ReversingGap Up & Comprehensive Market Scan Insights - newsyoung.net
Amneal Pharmaceuticals Inc. Reversal Rally May Surprise BearsMarket Movers & Safe Capital Growth Tips - sundaytimes.kr
How Amneal Pharmaceuticals Inc. stock performs during market volatility2025 Top Gainers & Intraday High Probability Setup Alerts - thegnnews.com
Is Amneal Pharmaceuticals Inc. showing insider buyingNew Guidance & Breakout Confirmation Alerts - thegnnews.com
Major Insider Sales Shake Up Amneal Pharmaceuticals! - TipRanks
Amneal Pharma EVP Shah sells $666k in shares By Investing.com - Investing.com Canada
Quant Funds Rotate Into Amneal Pharmaceuticals Inc. StockJuly 2025 Final Week & Weekly Stock Performance Updates - sundaytimes.kr
Can Amneal Pharmaceuticals Inc. expand into new marketsWeekly Investment Report & Weekly Stock Breakout Alerts - kangso.co.kr
Amneal Pharmaceuticals stock hits 52-week high at 9.48 USD By Investing.com - Investing.com Australia
Amneal Pharmaceuticals stock hits 52-week high at 9.48 USD - Investing.com
Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High? - Yahoo Finance
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know - Yahoo Finance
Amneal Will End Sale of Calcium-Drip Copies in Patent-Suit Pact - Bloomberg Law News
Amneal Pharmaceuticals Insider Sold Shares Worth $302,596, According to a Recent SEC Filing - MarketScreener
Here's Why Momentum in Amneal (AMRX) Should Keep going - Yahoo Finance
AMRX Q2 Deep Dive: New Product Launches and Specialty Momentum Shape Guidance - ca.finance.yahoo.com
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know - TradingView
Is Amneal Pharmaceuticals Inc. forming a bullish divergenceGuaranteed Profit Setup Watchlist - newsyoung.net
Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT - MSN
Brown Rudnick Represents Amneal Pharmaceuticals LLC in a $2.1 Billion Term Loan Credit Facility - Brown Rudnick
‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs - insights.citeline.com
Amneal Pharmaceuticals Inc. Stock Poised for Technical ComebackRisk Controlled Picks With Real Returns Outlined - beatles.ru
Published on: 2025-08-11 02:04:05 - metal.it
Amneal raises 2025 guidance and targets $300M–$500M peak CREXONT sales as new launches accelerate - MSN
Published on: 2025-08-10 19:02:24 - metal.it
Earnings Beat: Amneal Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - ca.finance.yahoo.com
Amneal 2025 Q2 Earnings Strong Performance as Net Income Surges 112% - AInvest
Amneal (AMRX) Q2 EPS Jumps 56% - AOL.com
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Amneal Pharma Reports Strong Q2 2025 Results - The Globe and Mail
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals Reports Strong Q2 2025 Results - The Globe and Mail
Amneal Pharmaceuticals Q2 2025 Earnings: EPS Beats Estimates, Revenue Falls Short - AInvest
Amneal: Q2 Earnings Snapshot - New Haven Register
Amneal Pharmaceuticals Inc (AMRX) Q2 2025 Earnings Call Highlights: Strong Growth and Raised ... By GuruFocus - Investing.com Canada
Amneal Pharma’s Optimistic Q2 Earnings Call Highlights - TipRanks
Amneal Pharmaceuticals' 2025Q2 Earnings Call: Key Contradictions on RYTARY, CREXONT, and Margin Strategies - AInvest
AMNEAL PHARMACEUTICALS Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast - Investing.com
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals Stock Rises Amid Growth Signals - TipRanks
Amneal Pharmaceuticals shares rise 5.53% intraday after revising earnings guidance and raising fiscal 2025 outlook. - AInvest
Transcript : Amneal Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Amneal Raises Outlook Even As Revenue Falls Short - Finimize
Knight Therapeutics Submits CREXONT Marketing Authorization Application in Mexico - AInvest
Amneal Pharmaceuticals Lifts Annual Earnings Outlook As Q2 Net Income Surges; Pre-Market Stock Up - Nasdaq
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates - Yahoo Finance
Amneal Pharmaceuticals Surpasses Q2 Earnings ExpectationsNews and Statistics - IndexBox
Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2025 - MarketScreener
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amneal Pharmaceuticals Inc Azioni (AMRX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Shah Nikita | Executive Vice President |
Aug 25 '25 |
Sale |
9.50 |
6,340 |
60,230 |
146,403 |
BOYER ANDREW S | Executive Vice President |
Aug 20 '25 |
Option Exercise |
2.75 |
175,000 |
481,250 |
431,670 |
BOYER ANDREW S | Executive Vice President |
Aug 20 '25 |
Sale |
9.38 |
279,244 |
2,619,309 |
152,426 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):